Accelerating Global Access for Indication Extension Through Regulatory Reliance Pilot: The First Indication Extension...

Area of Science:

• Pharmaceutical Regulatory Affairs
• Global Health Policy
• Drug Development

Background:

• Regulatory reliance pathways are crucial for accelerating medicine access and building capacity in National Regulatory Authorities (NRAs).
• Previous reliance pilots focused mainly on Chemistry, Manufacturing, and Controls (CMC) post-approval changes, with limited application to labeling variations like indication extensions.

Purpose of the Study:

• To describe the first regulatory reliance pilot specifically for an indication extension.
• To evaluate the impact of this pilot on approval timelines, regulatory convergence, and inter-authority communication.
• To identify success factors and challenges in implementing reliance pathways for indication extensions.

Main Methods:

• Engaged 21 National Regulatory Authorities (NRAs) across multiple regions in a reliance pilot.
• Utilized the European Medicines Agency (EMA) as the reference agency.
• Incorporated an optional digital platform for real-time sharing of questions and responses among participating authorities.

Main Results:

• Achieved a significant reduction in approval timelines, averaging 3 months shorter per country compared to standard processes.
• Demonstrated the feasibility and benefits of regulatory reliance for indication extensions.
• Facilitated streamlined communication and enhanced transparency among participating regulatory authorities.

Conclusions:

• Regulatory reliance for indication extensions substantially improves efficiency in regulatory processes.
• This approach significantly reduces approval timelines, leading to more timely global patient access to essential medicines.
• The pilot provides a model for optimizing regulatory processes and promoting international collaboration.